<DOC>
	<DOC>NCT00148915</DOC>
	<brief_summary>The purpose of this randomized, double-blind, placebo-controlled study is to estimate the effect of oral ibandronate sodium (Boniva) taken once monthly versus placebo on bone quality and strength at the proximal femur at one year.</brief_summary>
	<brief_title>A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criteria: Ambulatory, postmenopausal women between the age of 55 to 80 years diagnosed with osteoporosis BMD TScore less than or equal to (&lt;=) 2.0 at total spine or total femur or total neck, and BMD Tscore greater than or equal to (&gt;=) 5.0 at all 3 sites Exclusion criteria: Have been treated with other bisphosphonates or using chronic steroids within the past 6 months Have a history of major upper gastrointestinal (GI) diseases or have severe kidney dysfunction Have a spine fracture (identified on Xray)</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>bisphosphonates</keyword>
	<keyword>bone</keyword>
</DOC>